Abionyx Pharma SA
ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases. It develops CER-001, a negatively-charged lipoprotein particle that contains human recombinant apoA-I, the natural high-density lipoprotein (HDL) protein, and sphingomyelin and dipalmitoylphosphatidylglycerol natural phospholipids designed to mimic the structural and fu… Read more
Abionyx Pharma SA (ABNX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.314x
Based on the latest financial reports, Abionyx Pharma SA (ABNX) has a cash flow conversion efficiency ratio of -0.314x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-1.70 Million) by net assets (€5.41 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Abionyx Pharma SA - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Abionyx Pharma SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Abionyx Pharma SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Abionyx Pharma SA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ADF Group Inc
PINK:ADFJF
|
0.022x |
|
Daewon Cable Co. Ltd. Preference Shares
KO:006345
|
-0.036x |
|
G2Power Co. Ltd.
KQ:388050
|
-0.043x |
|
MaxCyte Inc
NASDAQ:MXCT
|
-0.041x |
|
AFFINITY BANCSHS DL-01
F:5610
|
N/A |
|
Westbury Bancorp Inc
PINK:WBBW
|
N/A |
|
Compagnie du Cambodge
PA:CBDG
|
0.004x |
|
Gs Global
KO:001250
|
-0.039x |
Annual Cash Flow Conversion Efficiency for Abionyx Pharma SA (2013–2024)
The table below shows the annual cash flow conversion efficiency of Abionyx Pharma SA from 2013 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €7.42 Million | €-3.60 Million | -0.485x | -3.88% |
| 2023-12-31 | €7.92 Million | €-3.70 Million | -0.467x | +0.37% |
| 2022-12-31 | €7.17 Million | €-3.36 Million | -0.469x | +25.24% |
| 2021-12-31 | €10.68 Million | €-6.69 Million | -0.627x | -593.63% |
| 2020-12-31 | €6.63 Million | €-599.00K | -0.090x | +84.75% |
| 2019-12-31 | €6.67 Million | €-3.95 Million | -0.593x | +62.11% |
| 2018-12-31 | €3.84 Million | €-6.00 Million | -1.564x | -52.89% |
| 2017-12-31 | €8.89 Million | €-9.09 Million | -1.023x | +22.15% |
| 2016-12-31 | €14.61 Million | €-19.20 Million | -1.314x | -218.16% |
| 2015-12-31 | €33.20 Million | €-13.71 Million | -0.413x | +99.85% |
| 2014-12-31 | €12.00K | €-3.30 Million | -275.250x | -11602.83% |
| 2013-12-31 | €6.16 Million | €-14.49 Million | -2.352x | -- |